Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Bifonazole spray once daily
Bifonazole once daily · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Arm 2 | EXPERIMENTAL | - |
| Arm 3 | PLACEBO_COMPARATOR | - |
| Arm 4 | PLACEBO_COMPARATOR | - |
| Arm 5 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Bifonazole spray once daily | DRUG | Application of one dose daily by means of an metered dose |
| Bifonazole spray twice daily | DRUG | Application of two dose daily by means of an metered dose |
| Placebo | DRUG | Application of one dose daily by means of an metered dose |
| Lamisil Once | DRUG | One application of Lamisil Once |
Inclusion Criteria: * Male or female subjects aged between 18 and 70 years * Positive clinical findings of athlete's foot, limited to interdigital spaces, with a total athlete's foot severity score (AFSS) of at least 5 and not exceeding 10 points for the signs and symptoms of athlete's foot, and no...
Bifonazole once daily is an investigational topical treatment being studied for tinea pedis, commonly known as athlete's foot. It is a small molecule antifungal developed by Bayer AG. The formulation is designed for once-daily application to the affected skin area.
Bifonazole once daily is developed by Bayer AG, which trades on the OTC market under the ticker BAYRY. Bayer is the sponsor of the clinical program evaluating this topical antifungal formulation for tinea pedis.
Bifonazole once daily is in Phase 2 clinical development for tinea pedis. It is investigational and has not been approved by the FDA for this use. The program includes one completed Phase 2 trial, with no active trials currently listed.
Bifonazole once daily was evaluated in the completed Phase 2 trial NCT01013909, titled Comparative Safety and Efficacy Study of New Bifonazol Spray vs Terbinafine Solution vs Placebo. The trial enrolled 220 participants in Germany, was randomized and placebo-controlled, and included adults 18 years and older of all sexes.
Yes, bifonazole once daily is also known as bifonazole spray once daily. Both names refer to the same Bayer AG topical antifungal product candidate being studied for tinea pedis. The spray formulation is the dosage form used in the Phase 2 trial.
Bifonazole once daily is a small molecule antifungal. It is applied topically as a spray to treat tinea pedis, a fungal infection of the feet. The once-daily dosing schedule is intended to simplify treatment compared with more frequent application regimens.